BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart

Jérôme Piquereau, Frédéric Perros

To cite this version:

Jérôme Piquereau, Frédéric Perros. BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart. American Journal of Respiratory and Critical Care Medicine, American Thoracic Society, 2019, 200 (9), pp.1187-1188. 10.1164/rrcm.201905-0993LE. inserm-02567794

HAL Id: inserm-02567794
https://www.hal.inserm.fr/inserm-02567794
Submitted on 8 May 2020

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L’archive ouverte pluridisciplinaire HAL, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d’enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.
BET Bromodomain Inhibitors and Pulmonary Arterial Hypertension: Take Care of the Heart

To the Editor:

We read with great interest the article by Van der Feen and colleagues (1), who reported the promising results from a multicenter preclinical validation of BET (bromodomain and extraterminal motif) family inhibition for the treatment of pulmonary arterial hypertension (PAH). The BET family members are epigenetic readers that bind acetylated proteins, facilitating the localization of transcription factors and other coactivators to upregulate transcription (2). BET family proteins have been implicated in cardiac pathologic gene induction and heart failure pathogenesis. Indeed, pharmacological administration of several BET inhibitors had significant therapeutic effects in a diverse range of small animal models of heart failure via a mechanism that converges on suppression of profibrotic and proinflammatory gene expression programs in the heart (3). The role of BET proteins has also been studied in the frame of PAH and associated right ventricle (RV) hypertrophy and failure (4). In their study, Van der Feen and colleagues (1) demonstrated that RVX208, a clinically available BET inhibitor, modulates pro-proliferative, prosurvival, and proinflammatory pathways. This reversed the PAH phenotype in cultured pulmonary vascular cells and improved pulmonary hemodynamics and RV function in several animal models of PAH and isolated RV pressure load.

Paradoxically, we recently demonstrated that in vivo administration of BET inhibitor I-BET-151 induces structural and functional alterations of the heart mitochondria in healthy male mice and rats (5). We showed the occurrence of specific ultrastructural alterations and progressive destruction of cardiomyocyte mitochondria after I-BET-151 exposure, whereas the skeletal muscles of exposed animals were unaffected. In rats, I-BET-151 decreased the oxidative capacities of cardiac mitochondria in a dose-dependent manner, and at high dose (10 mg/kg/d during 3 wk), it also decreased mitochondrial mass. I-BET-151 reduced the right and left ventricular fractional shortening and decreased the velocity–time integral in the aorta and the pulmonary artery. Both functional reductions are suggestive of impaired heart function under I-BET-151 exposure. Although a 3-week washout period allowed a partial restoration of mitochondrial structure in the RV and an improvement of left ventricle function, full normalization of both mitochondrial morphology and ventricular function was not observed in either the RV nor the left ventricle. The ultrastructural alterations of heart mitochondria we observed in healthy mice and rat exposed to I-BET-151 may be partly a result of c-Myc inhibition (5, 6).

Several BET inhibitors are currently being evaluated in phase 1 clinical trials, and promising results have been obtained in several lymphomas, as well as some solid tumors. One of these trials was conducted to evaluate for the first time the toxicity and efficacy of BET inhibitor BAY1238097 in humans (2). Although this study showed that the drug did inhibit its target, several patients reported unexpected pain (headache and back pain) occurring shortly after taking the drug. These toxicities were not observed in the preclinical tests and differed from the reported toxicities with the other BET inhibitors, suggesting they were related to an off-target effect. Further study of the clinical and preclinical data revealed that BAY1238097 also binds the adenosine receptor, potentially increasing the concentration of mediators involved in the pain. The occurrence of these pains at doses lower than doses that would have been effective in clinics led to the cessation of the development of this drug. However, this negative test has been reported because it could inform the development of other BET inhibitors.

In conclusion, BET inhibitors hold promising potential as a new therapy for left and right heart failure and PAH. However, the BET family of proteins regulates a vast network of transcriptional pathways, raising concerns regarding their safety. Attention must be paid about possible off-target effects of BET inhibitors, as well as potential cardiotoxicity of this new therapeutic class.
Epigenetic regulation of chromatin structure is fundamental to development and disease states (1, 2). Importantly, acetylation and methylation of histone tails and methylation of DNA by a specific group of enzymes are the most common epigenetic modifications that occur at specific sites and residues (3). For example, histone acetyltransferases acetylate histone tails, histone deacetylases remove acetyl groups from histone tails, and BRD (bromodomain) proteins are chromatin readers that recognize and bind acetylated histones. The latter also play a key role in the transmission of epigenetic memory across cell divisions and transcription regulation, and thus have emerged as an attractive drug class for the treatment of cancer and other nonmalignant disorders (4–6).

Pulmonary arterial hypertension (PAH; group 1 pulmonary hypertension [PH]) is a progressive pulmonary vascular disease with a poor prognosis that culminates in right heart failure. Despite our progressive understanding of the pathogenesis of PAH and recent therapeutic advances, PAH remains a fatal disease (7). Several lines of evidence suggest the contribution of epigenetic mechanisms to vascular remodeling in PH/PAH. First, both the initiation and progression of PH/PAH are influenced by environmental factors, and thus it has been speculated that exposure to viruses, drugs, toxins, hypoxia, and inflammation drives epigenetic mechanisms underlying PH/PAH pathogenesis. Second, PAH is also a genetic disease, and genetic factors also influence epigenetic mechanisms. Third, epigenetic modifications are also crucial for the persistent activation of PAH vascular cells when cultured ex vivo, a hallmark feature of PAH. Finally, emerging evidence suggests that the pathogenesis of PH is influenced by aberrant expression and activity of DNA and histone-modifying enzymes (8, 9), including upregulation of BRD4.

Accordingly, earlier studies demonstrated that pan-BRD (JQ1 and I-BET-151) and selective BRD4 knockdown inhibited pulmonary arterial smooth muscle cell proliferation and restored mitochondrial membrane potential in patients with PAH (10), and prevented the production of proinflammatory cytokines by pulmonary microvascular endothelial cells (11). Importantly, studies showed that pan-BRD inhibitors reversed established PAH in the Sugen/hypoxia microvascular endothelial cells (11). Importantly, studies showed that pan-BRD inhibitors reversed established PAH in the Sugen/hypoxia microvascular endothelial cells (11). Importantly, studies showed that pan-BRD inhibitors reversed established PAH in the Sugen/hypoxia microvascular endothelial cells (11).

In the setting of a multicenter preclinical trial, Van der Feen and colleagues report that apabetalone (RVX-208), a clinically available domain-selective BET inhibitor, reversed vascular remodeling and improved pulmonary hemodynamics in several experimental models of PAH (14). This study provides convincing data, obtained both in vitro and in vivo, indicating that apabetalone normalized the hyperproliferative, apoptosis-resistant and proinflammatory phenotype of microvascular endothelial cells and pulmonary arterial smooth muscle cells isolated from patients with PAH, as well as in animal models of PAH (Figure 1). Importantly, at a clinically relevant dose, RVX-208 reversed vascular remodeling in multiple complementary preclinical models of PAH and could be combined safely with current PAH therapy. Finally, apabetalone was shown to support the pressure-loaded right ventricle in rats, indicating a beneficial, dual mode of action for patients with PAH-associated right-ventricle pressure overload. Based on these exciting preclinical results, a 16-week phase 2 pilot study (ClinicalTrials.gov identifier: NCT01819782) is currently ongoing in the setting of a multicenter preclinical trial.